← Leaderboards
Peter A Cohen
Cleveland Clinic Foundation
$9,427,938
Attributed
$12,042,714
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$12,042,714 · 6
By mechanism
R01$10,120,951 · 5
P50$1,921,763 · 1
Top collaborators
- Mary L. Disis5 shared
- James H Finke5 shared
Most similar at Cleveland Clinic Foundation
Same institution · by research overlap
- James H Finke$9,274,196
- Gregory E Plautz$2,534,015
- Suyu Shu$4,156,854
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorT-LymphocyteCellsMalignant NeoplasmsImmunotherapyResponseNeoplastic CellClinical TrialsCytokineImmune SystemElementsImmune ResponseIn VitroMelanomaDendritic CellsExposure ToPredispositionCancer PatientCell Differentiation ProcessVaccinesAnimalsTumor ProgressionAgonistStaging
Grant awards (31)
Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer$401,334
P50 · FY2018 · CA · contact PI
Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer$387,183
P50 · FY2017 · CA · contact PI
Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer$376,909
P50 · FY2016 · CA · contact PI
Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer$381,692
P50 · FY2015 · CA · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy$570,144
R01 · FY2014 · CA
Sunitinib Modulation of Cancer Immunotherapy$501,600
R01 · FY2014 · CA
Role of Macrophage Regulatory Cells (Mac-regs) in Immune Regulation$410,000
R01 · FY2014 · AI · contact PI
Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer$374,645
P50 · FY2014 · CA · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy$554,758
R01 · FY2013 · CA
Sunitinib Modulation of Cancer Immunotherapy$491,332
R01 · FY2013 · CA
Role of Macrophage Regulatory Cells (Mac-regs) in Immune Regulation$385,400
R01 · FY2013 · AI · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy$611,011
R01 · FY2012 · CA
Sunitinib Modulation of Cancer Immunotherapy$528,446
R01 · FY2012 · CA
Role of Macrophage Regulatory Cells (Mac-regs) in Immune Regulation$410,000
R01 · FY2012 · AI · contact PI
Sunitinib Modulation of Cancer Immunotherapy$548,705
R01 · FY2011 · CA
Role of Macrophage Regulatory Cells (Mac-regs) in Immune Regulation$375,834
R01 · FY2011 · AI · contact PI
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.$572,160
R01 · FY2010 · CA
PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS$304,000
R01 · FY2010 · CA · contact PI
Sunitinib Modulation of Cancer Immunotherapy$268,456
R01 · FY2010 · CA
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.$582,940
R01 · FY2009 · CA
PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS$304,000
R01 · FY2009 · CA · contact PI
PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS$161,745
R01 · FY2008 · CA · contact PI
PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS$131,805
R01 · FY2008 · CA · contact PI
CD8+ HELPER-INDEPENDENT T CELLS IN TUMOR THERAPY$293,771
R01 · FY2007 · CA · contact PI
PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS$293,550
R01 · FY2007 · CA · contact PI
CD8+ HELPER-INDEPENDENT T CELLS IN TUMOR THERAPY$302,544
R01 · FY2006 · CA · contact PI
CD8+ HELPER-INDEPENDENT T CELLS IN TUMOR THERAPY$309,825
R01 · FY2005 · CA
CD8+ HELPER-INDEPENDENT T CELLS IN TUMOR THERAPY$309,825
R01 · FY2004 · CA
CD8+ HELPER INDEPENDENT T CELLS IN TUMOR THERAPY$299,700
R01 · FY2003 · CA
CD8+ HELPER INDEPENDENT T CELLS IN TUMOR THERAPY$299,700
R01 · FY2002 · CA
CD8+ HELPER INDEPENDENT T CELLS IN TUMOR THERAPY$299,700
R01 · FY2001 · CA